<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306484</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2020/DR-01</org_study_id>
    <nct_id>NCT04306484</nct_id>
  </id_info>
  <brief_title>18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions</brief_title>
  <acronym>FDOPA</acronym>
  <official_title>18F-DOPA-PET in Non-tumoral and Tumoral Brain Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA) positron emission tomography
      (PET) can identify well low and high grade brain tumors. However, increased FDOPA uptake has
      been reported in non-tumoral brain lesions. The aim was to analyse FDOPA-PET in patients with
      non-tumoral brain lesions and to compare them with patients with (low and high grade) brain
      tumors.

      Methods: retrospective analyse. Patients consecutively recruited with suspected primary brain
      tumor (based on clinical and MRI findings) referred for FDOPA-PET at Nimes university
      Hospital between June 2015 and June 2019. FDOPA-PET parameters (maximum and mean lesion
      standardized uptake values [SUV] and ratios comparing lesion with different background uptake
      SUV) and thresholds were analysed in search for those offering optimal discrimination between
      non-tumoral and tumoral lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>FDOPA-TEP</measure>
    <time_frame>Day 1</time_frame>
    <description>analyse of FDOPA-PET parameters (maximum and mean lesion standardized uptake values [SUV] and ratios comparing lesion with different background uptake SUV)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">74</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>patients with tumoral brain lesion</arm_group_label>
    <description>The 48 tumor patients included 8 low grade (grade II glioma, n=7; grade II ependymoma, n=1), and 40 high grade (grade III glioma, n=12; grade IV glioma, n=25, primary cerebral lymphoma, n=1; medulloblastoma, n=1, and metastatic cerebral breast cancer, n=1) tumors. Histology was available for all tumor patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with non-tumoral brain lesion</arm_group_label>
    <description>The non-tumor group included patients with an inflammatory lesion (n=11), lobar primary intracerebral haemorrhage (n=3), cortical dysplasia (n=3), infectious lesion (n=2, both toxoplasmosis), cerebral cavernomatous malformation (n=1), seronegative autoimmune limbic encephalitis (n=1), deep venous sinus thrombosis-related oedema (n=1), brain infarction (n=1), chronic posttraumatic brain lesion (n=1), radionecrosis after radiation therapy for arteriovenous malformation (n=1), and mixed inflammatory/infectious lesion (n=1, multiple sclerosis lesion complicated by biopsy-related infection).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FDOPA-TEP</intervention_name>
    <description>FDOPA-TEP performed as part of the normal management of a suspected brain tumour</description>
    <arm_group_label>patients with non-tumoral brain lesion</arm_group_label>
    <arm_group_label>patients with tumoral brain lesion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with suspected primary brain tumor (based on clinical and MRI findings) referred
        for FDOPA-PET in our centre between June 2015 and June 2019
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of defined tumor (histology was required) or non-tumor (diagnosed by
             histological or other analyses) diagnosis,

          -  clinical and MRI follow-up of &gt;24 months,

          -  FDOPA-PET scan &lt;2 months before surgery or stereotactic biopsy (when performed)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tumor</keyword>
  <keyword>tumoral</keyword>
  <keyword>non-tumoral</keyword>
  <keyword>pseudotumoral</keyword>
  <keyword>3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine</keyword>
  <keyword>FDOPA</keyword>
  <keyword>positron emission tomography</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

